Shares of Supriya Lifescience surged more than 16% in early trade on Friday after the pharmaceutical company reported a strong set of quarterly numbers and reiterated its growth outlook for the coming years.
The stock was trading at ₹938 on the NSE at around 9:51 AM, up 16.2% from its previous close of ₹807.25. The stock touched an intraday high of ₹943.80, which also marked a fresh 52-week high.
For the quarter ended March 2026, the company reported revenue of ₹276.53 crore, registering a growth of 50.2% year-on-year from ₹184.11 crore and a 33.9% increase compared with ₹206.44 crore reported in the previous quarter.
Profit before tax rose 43.8% YoY to ₹92.13 crore from ₹64.06 crore, while profit after tax increased 47.3% to ₹74.23 crore from ₹50.38 crore in the corresponding quarter last year. On a sequential basis, net profit grew 49.4% from ₹49.67 crore reported in Q3 FY26.
EBITDA stood at ₹97.62 crore, up 44.4% from ₹67.59 crore a year ago and 35.4% higher than ₹72.08 crore reported in the previous quarter.
EBITDA margin came in at 35.75%, compared with 37.31% in Q4 FY25 and 35.36% in Q3 FY26. Operating income increased 44.9% year-on-year to ₹89.12 crore, while earnings per share rose 46.6% to ₹9.22.
Along with the earnings announcement, management reiterated its confidence in achieving approximately 20% annual revenue growth and maintained its target of reaching ₹1,000 crore in revenue by FY27.
The company, however, noted that growth may not be linear across quarters due to a planned annual maintenance shutdown scheduled during Q2 FY27. Despite this, management remains confident about the long-term growth trajectory of the business.
Supriya Lifescience also guided for EBITDA margins in the range of 33% to 35%, indicating that profitability is expected to remain healthy even as newly launched products scale up in semi-regulated markets before moving into higher-margin regulated markets.
The strong earnings performance, coupled with the reaffirmed revenue and margin guidance, appears to have boosted investor sentiment, driving the stock to a new 52-week high in Friday’s session.
Meanwhile, Supriya Lifescience shares were trading 16.2% higher at ₹938 on the NSE at the time of publishing this article after touching a fresh 52-week high of ₹943.80 earlier in the day.
Disclaimer: This article is for informational purposes only and should not be construed as investment advice. Investors should consult qualified financial advisers before making investment decisions.